10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-Occludin Antibody

Catalog # AP61238

Product Information

Application	WB, IF/IC
Primary Accession	Q16625
Reactivity	Human, Mouse, Rat, Dog
Host	Rabbit
Clonality	Polyclonal
Calculated MW	59144

Additional Information


Gene ID	100506658
Other Names	Occludin
Target/Specificity	KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human Occludin. The exact sequence is proprietary.
Dilution	WB~~WB (1/500 - 1/1000) IF/IC~~N/A
Format	Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide.
Storage	Store at -20 °C.Stable for 12 months from date of receipt

Protein Information


Name	OCLN
Function	May play a role in the formation and regulation of the tight junction (TJ) paracellular permeability barrier. It is able to induce adhesion when expressed in cells lacking tight junctions.
Cellular Location	Cell membrane; Multi-pass membrane protein. Cell junction, tight junction
Tissue Location	Localized at tight junctions of both epithelial and endothelial cells. Highly expressed in kidney. Not detected in testis

Images

Western blot analysis of Occludin expression in mouse kidney (A), rat kidney (B) whole cell lysates. (Predicted



band size: 59 kD; Observed band size: 60 kD)



Immunofluorescent analysis of Occludin staining in MCF7 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a hidified chamber. Cells were washed with PBST and incubated with a AF488-conjugated secondary antibody (green) in PBS at room temperature in the dark. Phalloidin - AF594 was used to stain Actin filaments (red). DAPI was used to stain the cell nuclei (blue).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.